UNSPSC 51284128: Cefetamet pivoxil

This classification denotes a cephalosporin antibiotic C20H25N5O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F6XA85N260, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-methyl-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6r-(6.alpha.,7.beta.(z)))-, but more generally known as cefetamet pivoxil, which bears US NIH Compound Identifier 5486182.

UNSPSC 51284128 Cefetamet pivoxil is a Commodity code for a specific antibiotic pharmaceutical product, but the recent state and local activity tagged under this code does not reflect procurement of cefetamet pivoxil itself. Instead, the opportunities captured show state and local health agencies and county governments purchasing other pharmaceutical products—including antibiotic tablets (Doxycycline Hyclate, Ciprofloxacin Hydrochloride) through cooperative purchasing arrangements and emergency-response medications (Naloxone) through competitive bidding. State and local buyers under this code segment include state departments of public health and county health authorities, which typically procure through piggyback contracts tied to multi-agency cooperative purchasing consortia or through straightforward IFB processes. The mismatch between the nominal code scope (cefetamet pivoxil) and the actual recent opportunities suggests this Commodity code may be misapplied in the source data or represents a pharmaceutical category bucket rather than the specific active pharmaceutical ingredient named.

Recent activity is geographically dispersed: the Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for antibiotic tablets on a 12-month initial term with two renewal options, while Seminole County, Florida released an IFB in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries and a July 26, 2026 response deadline. The Illinois procurement was a completed award, not an open solicitation. Given the product mismatch and the thin pipeline of recent opportunities explicitly tied to this Commodity code, activity appears limited; firms should verify whether their product lines align with how their target state and local jurisdictions actually code pharmaceutical procurements.